UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

By: Benzinga
Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS ) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00. Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.